The Modern Metabolic Peptides: A Research Guide to GLP-1, Dual, and Triple Agonists

Summary

The most active area in metabolic peptide research today is a family of compounds that mimic or amplify the body's own incretin hormones. What began with single-target GLP-1 compounds has expanded into dual and triple agonists that engage several metabolic pathways at once. This guide explains what these peptides are and how each generation was designed to recruit more of the body's metabolic machinery.

Why This Matters

This class is the fastest-moving area in metabolic research, and it connects directly to Pepvela's "test first" principle. These compounds act on glucose, insulin, appetite, and in some cases liver fat, the same systems your biomarkers measure. This article explains the science; your biomarkers explain you.

What Are Incretins?

Incretins are hormones your gut releases in response to food, and they work through several receptor systems that each play a different metabolic role.

GLP-1 slows stomach emptying, supports insulin release when blood sugar rises, and reduces appetite. It became the foundation of the entire class.

GIP is a second incretin that supports insulin secretion and appears to influence how fat tissue handles energy. On its own its role is subtle, but combined with GLP-1 it adds to the effect.

Glucagon is best known for raising blood sugar, but at the doses studied here, activating its receptor appears to increase energy expenditure and promote breakdown of fat in the liver, which makes it an interesting third target.

Amylin sits alongside the incretins: a hormone that contributes to fullness and slows gastric emptying, representing a related but distinct pathway.

Each compound in this class is essentially a different combination of which of these receptors it engages.

The Staircase: Single, Dual, and Triple Agonists

The clearest way to understand these peptides is as a progression. Each generation was designed to engage more receptor systems at once, based on the research observation that recruiting additional pathways tends to broaden the metabolic effect.

Single-receptor (GLP-1 alone). Semaglutide and liraglutide are GLP-1 agonists, and they established the foundation. Semaglutide became one of the most widely studied compounds in metabolic medicine, available in injectable and, more recently, oral forms.

Dual-receptor. The next step engaged two pathways with one molecule, in two different ways. Tirzepatide combines GLP-1 with GIP. Survodutide pairs GLP-1 with glucagon, and because glucagon acts on liver fat, it has been studied with particular attention to metabolic liver disease. Mazdutide is another GLP-1 and glucagon agonist in research. The choice of second receptor shapes the profile.

Triple-receptor. Retatrutide engages all three incretin-related receptors at once (GLP-1, GIP, and glucagon), making it the most comprehensive incretin-based approach studied to date. It is in large Phase 3 trials and remains investigational.

The amylin-adjacent path. Separately, some compounds pair GLP-1 with the amylin pathway rather than GIP or glucagon. Cagrilintide is an amylin analog studied in combination with semaglutide. This is a parallel line of research rather than another step on the same staircase.

The through-line: the research direction has been to engage more of the body's own metabolic signaling, testing whether additional pathways add to the effect. Some of these compounds are FDA approved for specific uses; many others remain investigational and are not approved for human use.

The Biomarkers That Matter

Because these compounds act on the core machinery of metabolism, several biomarkers give useful context, interpreted with a licensed provider:

• Fasting glucose and HbA1c reflect blood sugar management over the short and longer term.
• Fasting insulin offers a window into insulin resistance, often before glucose shifts.
• Liver enzymes matter because several of these compounds are studied in the context of liver fat.
• ApoB gives context on cardiovascular risk, which is intertwined with metabolic health.

Establishing these values before any research protocol, and tracking them over time with a qualified provider, is the heart of the "test before you stack" approach.

Continue Your Research

Explore the individual research profiles for the compounds discussed here, and use Pepvela's tools to understand your baseline first.